Skip to main content

The context you need, when you need it

When news breaks, you need to understand what actually matters — and what to do about it. At Vox, our mission to help you make sense of the world has never been more vital. But we can’t do it on our own.

We rely on readers like you to fund our journalism. Will you support our work and become a Vox Member today?

Join now

Venture-Backed U.S. IPOs Hit Lowest Levels in Two Years

Life sciences companies dominated the IPO market.

Spencer Platt / Getty

U.S. initial public offerings by venture-backed companies fell to a two-year low in the first quarter of 2015, according to data from the National Venture Capital Association and Thomson Reuters.

About 17 venture-backed companies raised $1.43 billion in the three months ending in March, compared with 37 that raised $3.40 billion in the same period a year earlier, according to the report.

The last time the number fell below 20 was in the first quarter of 2013, when eight venture-backed companies raised $716.9 million.

Box, an online data storage provider, had the biggest IPO in the latest quarter, raising $201.2 million. It began trading on the New York Stock Exchange on Jan. 22.

Life sciences companies dominated the IPO market, with 13 of the 17 offerings coming from the sector.

The average amount raised was $84.3 million, down from $92 million in the first quarter of 2014.

Among venture-backed mergers and acquisitions, only 16 of the 86 during the quarter reported deal size. The average deal size was $128.1 million, compared with $245.8 million a year earlier.

(Reporting by Anil D’Silva in Bengaluru; Editing by Sriraj Kalluvila)

This article originally appeared on Recode.net.

More in Technology

Podcasts
Are humanoid robots all hype?Are humanoid robots all hype?
Podcast
Podcasts

AI is making them better — but they’re not going to be doing your chores anytime soon.

By Avishay Artsy and Sean Rameswaram
Future Perfect
The old tech that could help stop the next airborne pandemicThe old tech that could help stop the next airborne pandemic
Future Perfect

Glycol vapors, explained.

By Shayna Korol
Future Perfect
Elon Musk could lose his case against OpenAI — and still get what he wantsElon Musk could lose his case against OpenAI — and still get what he wants
Future Perfect

It’s not about who wins. It’s about the dirty laundry you air along the way.

By Sara Herschander
Life
Why banning kids from AI isn’t the answerWhy banning kids from AI isn’t the answer
Life

What kids really need in the age of artificial intelligence.

By Anna North
Culture
Anthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque messAnthropic owes authors $1.5B for pirating work — but the claims process is a Kafkaesque mess
Culture

“Your AI monster ate all our work. Now you’re trying to pay us off with this piece of garbage that doesn’t work.”

By Constance Grady
Future Perfect
Some deaf children are hearing again because of a new gene therapySome deaf children are hearing again because of a new gene therapy
Future Perfect

A medical field that almost died is quietly fixing one disease at a time.

By Bryan Walsh